Building a better understanding of the burden of disease in familial chylomicronemia syndrome

Expert Rev Clin Pharmacol. 2017 Jan;10(1):1-3. doi: 10.1080/17512433.2017.1251839. Epub 2016 Nov 8.

Authors

Zahid Ahmad¹, Rob Halter², Michael Stevenson²

Affiliations

¹ a UT Southwestern , IM Subspecialties Clinic , Texas , USA.
² b Akcea Therapeutics , MA , USA.

PMID: 27771961
DOI: 10.1080/17512433.2017.1251839

No abstract available

Keywords: FCS; familial chylomicronemia syndrome; lipoprotein lipase; lipoprotein lipase deficiency; type 1 hyperlipoproteinemia.

MeSH terms

Cost of Illness*
Humans
Hyperlipoproteinemia Type I / diagnosis
Hyperlipoproteinemia Type I / physiopathology*
Hyperlipoproteinemia Type I / therapy

Supplementary concepts

Familial hyperchylomicronemia syndrome